Business
Gene sequencing company Illumina Inc will pay US$7.1 billion in cash and stock to buy cancer test startup Grail Inc, the Wall Street Journal reported on Monday, citing people familiar with the matter.
FILE PHOTO: A new office building housing genetic research company Illumina is shown in San Diego, California, U.S., May 30, 2018. REUTERS/Mike Blake
(Updated: )
Share this content
Bookmark
REUTERS: Gene sequencing company Illumina Inc will pay US$8 billion in cash and stock to buy cancer screening startup Grail Inc, the companies said on Monday.
Grail, which is developing a blood test to identify early-stage cancers, was founded by Illumina as a separate company in 2016 and is backed by Amazon.com Inc founder Jeff Bezos and billionaire philanthropist Bill Gates.
Advertisement
Advertisement
The deal would give Illumina access to Grail's test for early detection of cancer from blood called Galleri, which is expected to launch commercially in 2021.
Grail plans to follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer patients, the companies said.
Earlier this month Grail, in which Illumina is the biggest shareholder with a near 14.5per cent stake, filed for a U.S. initial public offering, without disclosing the offering size.
Under the terms of Read More – Source
